Trial Profile

A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early versus Delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary) ; Hydroxychloroquine; Methotrexate; Sulfasalazine
Indications Rheumatoid arthritis; Synovitis
Focus Therapeutic Use
Acronyms VEDERA

15 Jun 2024 Results identifying the inflammatory proteomic signature of concordance/discordance between clinical disease activity and joint inflammation, and the transitions between these states in a treatment-naive early RA cohort, presented at the 25th Annual Congress of the European League Against Rheumatism
04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism
29 Jan 2020 Primary endpoint has not been met. (Clinical remission)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com